321 related articles for article (PubMed ID: 11668219)
1. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.
Dai D; Zeldin DC; Blaisdell JA; Chanas B; Coulter SJ; Ghanayem BI; Goldstein JA
Pharmacogenetics; 2001 Oct; 11(7):597-607. PubMed ID: 11668219
[TBL] [Abstract][Full Text] [Related]
2. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes.
Rifkind AB; Lee C; Chang TK; Waxman DJ
Arch Biochem Biophys; 1995 Jul; 320(2):380-9. PubMed ID: 7625847
[TBL] [Abstract][Full Text] [Related]
3. Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism.
Soyama A; Saito Y; Hanioka N; Murayama N; Nakajima O; Katori N; Ishida S; Sai K; Ozawa S; Sawada JI
Biol Pharm Bull; 2001 Dec; 24(12):1427-30. PubMed ID: 11767116
[TBL] [Abstract][Full Text] [Related]
4. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
Henningsson A; Marsh S; Loos WJ; Karlsson MO; Garsa A; Mross K; Mielke S; Viganò L; Locatelli A; Verweij J; Sparreboom A; McLeod HL
Clin Cancer Res; 2005 Nov; 11(22):8097-104. PubMed ID: 16299241
[TBL] [Abstract][Full Text] [Related]
5. Functional characterization of CYP2C8.13 and CYP2C8.14: catalytic activities toward paclitaxel.
Hanioka N; Matsumoto K; Saito Y; Narimatsu S
Basic Clin Pharmacol Toxicol; 2010 Jul; 107(1):565-9. PubMed ID: 20148860
[TBL] [Abstract][Full Text] [Related]
6. Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes.
Yamazaki H; Shimada T
Xenobiotica; 1999 Mar; 29(3):231-41. PubMed ID: 10219964
[TBL] [Abstract][Full Text] [Related]
7. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension.
King LM; Gainer JV; David GL; Dai D; Goldstein JA; Brown NJ; Zeldin DC
Pharmacogenet Genomics; 2005 Jan; 15(1):7-13. PubMed ID: 15864120
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation.
Tsukada C; Saito T; Maekawa M; Mano N; Oda A; Hirasawa N; Hiratsuka M
Drug Metab Pharmacokinet; 2015 Oct; 30(5):366-73. PubMed ID: 26427316
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.
Baldwin SJ; Clarke SE; Chenery RJ
Br J Clin Pharmacol; 1999 Sep; 48(3):424-32. PubMed ID: 10510156
[TBL] [Abstract][Full Text] [Related]
10. Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation.
Rowbotham SE; Boddy AV; Redfern CP; Veal GJ; Daly AK
Drug Metab Dispos; 2010 Aug; 38(8):1261-6. PubMed ID: 20421446
[TBL] [Abstract][Full Text] [Related]
11. Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity.
Lee MY; Apellániz-Ruiz M; Johansson I; Vikingsson S; Bergmann TK; Brøsen K; Green H; Rodríguez-Antona C; Ingelman-Sundberg M
Pharmacogenomics; 2015; 16(9):929-37. PubMed ID: 26115084
[TBL] [Abstract][Full Text] [Related]
12. [Genetic polymorphism of the CYP2C subfamily].
Chiba K
Nihon Yakurigaku Zasshi; 1998 Jul; 112(1):15-21. PubMed ID: 9755458
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro.
Yu L; Shi D; Ma L; Zhou Q; Zeng S
Biopharm Drug Dispos; 2013 Jul; 34(5):278-87. PubMed ID: 23536207
[TBL] [Abstract][Full Text] [Related]
14. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms.
Yasar U; Lundgren S; Eliasson E; Bennet A; Wiman B; de Faire U; Rane A
Biochem Biophys Res Commun; 2002 Nov; 299(1):25-8. PubMed ID: 12435384
[TBL] [Abstract][Full Text] [Related]
15. Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes.
Mukai Y; Senda A; Toda T; Hayakawa T; Eliasson E; Rane A; Inotsume N
Basic Clin Pharmacol Toxicol; 2015 Jun; 116(6):493-8. PubMed ID: 25424246
[TBL] [Abstract][Full Text] [Related]
16. Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8.
García-Martín E; Pizarro RM; Martínez C; Gutierrez-Martín Y; Pérez G; Jover R; Agúndez JA
Pharmacogenomics; 2006 Jun; 7(4):575-85. PubMed ID: 16753005
[TBL] [Abstract][Full Text] [Related]
17. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate.
Li XQ; Björkman A; Andersson TB; Ridderström M; Masimirembwa CM
J Pharmacol Exp Ther; 2002 Feb; 300(2):399-407. PubMed ID: 11805197
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.
Daily EB; Aquilante CL
Pharmacogenomics; 2009 Sep; 10(9):1489-510. PubMed ID: 19761371
[TBL] [Abstract][Full Text] [Related]
19. Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease.
Smith HE; Jones JP; Kalhorn TF; Farin FM; Stapleton PL; Davis CL; Perkins JD; Blough DK; Hebert MF; Thummel KE; Totah RA
Pharmacogenet Genomics; 2008 Nov; 18(11):943-53. PubMed ID: 18769365
[TBL] [Abstract][Full Text] [Related]
20. Structural and functional insights into polymorphic enzymes of cytochrome P450 2C8.
Jiang H; Zhong F; Sun L; Feng W; Huang ZX; Tan X
Amino Acids; 2011 Apr; 40(4):1195-204. PubMed ID: 20848147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
